Off-Label Use of Rituximab in a Multipayer Insurance System-Reference-Cited by-同舟云学术

Off-Label Use of Rituximab in a Multipayer Insurance System

Published:2011-03 Issue:2 Volume:7 Page:76-79
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Van Allen Eliezer M.¹,Miyake Todd¹,Gunn Nathan¹,Behler Caroline M.¹,Kohlwes Jeff¹

Affiliation:

1. Department of Biology and Department of Economics, University of California, San Diego; Verisk Health, Waltham, MA; Department of Medicine, Department of Hematology/Oncology, and PRIME Residency Program, San Francisco Veterans Affairs Medical Center, San Francisco, CA; Department of Medicine, and Department of Malignant Hematology and Bone Marrow Transplant, University of California, San Francisco

Abstract

The frequent use of rituximab for off-label indications should lead to improved postapproval FDA surveillance of biologics so that use can be adequately studied, and will also facilitate improved regulatory mechanisms to ensure evidence-based use.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.2010.000042

Reference15 articles.

1. Bolstering the FDA's Drug-Safety Authority

2. Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation

3. Off-label Prescribing Among Office-Based Physicians

4. Off-label use of anticancer drugs

5. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronquiectasias, adenopatías relacionadas con la sobreexpresión del factor activador de los linfocitos B perteneciente a la familia del factor de necrosis tumoral y cistitis linfoplasmocítica como eventos adversos asociados al uso prolongado de rituximab en enfermedades reumáticas autoinmunes sistémicas;Revista Clínica Española;2024-08

2. Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases;Revista Clínica Española (English Edition);2024-08

3. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases;The FASEB Journal;2024-03-12

4. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience;Leukemia & Lymphoma;2023-10-27

5. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases;2023-09-25